ArticleCancer medicine2019
Oxaliplatin regulates myeloid-derived suppressor cell-mediated immunosuppression via downregulation of nuclear factor-κB signaling.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Potentiation of a Porous Silicon Therapeutic Vaccine in Colorectal Cancer via Oxaliplatin-Mediated Regulation of Myeloid-Driven Immunosuppression.Journal of functional biomaterials · 2026Article
- Article
- The Dynamic Changes of Circulating Myeloid-Derived Suppressor Cells (MDSCs) Subsets in Colorectal Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy.Journal of gastrointestinal cancer · 2025Article
- Immunopharmacology of gastric cancer-deciphering immune cell subset responses and nanoparticle-mediated targeting.Frontiers in pharmacology · 2025Review
- Immunotherapy resistance in solid tumors: mechanisms and potential solutions.Cancer biology & therapy · 2024Review
- Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy.Journal of nanobiotechnology · 2024Article
- Immunogenic cell death-based cancer vaccines: promising prospect in cancer therapy.Frontiers in immunology · 2024Review
- Induction of resistance to oxaliplatin in cancer by a microRNA/Fem1B/Gli1 pathway.American journal of cancer research · 2023Article
- Immunogenic chemotherapy: great potential for improving response rates.Frontiers in oncology · 2023Review
- Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment.Frontiers in pharmacology · 2022Review
- Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma.Frontiers in oncology · 2022Review
- Recent Advances in the Development of Noble Metal NPs for Cancer Therapy.Bioinorganic chemistry and applications · 2022Review
- Role of Myeloid-derived suppressor cell (MDSC) in autoimmunity and its potential as a therapeutic target.Inflammopharmacology · 2021Review
- Tumor-related stress regulates functional plasticity of MDSCs.Cellular immunology · 2021Review
- Immunity, immunotherapy, and rectal cancer: A clinical and translational science review.Translational research : the journal of laboratory and clinical medicine · 2021Review
- Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients.Oncoimmunology · 2021Article
- Review
- Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects.Clinical Medicine Insights. Oncology · 2021Review
- Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy.Cancers · 2020Review
- Jianpi Huayu Decoction Attenuates the Immunosuppressive Status of HFrontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid-derived suppressor cells (MDSCs) represent one of the major types of immunoregulatory cells present under abnormal conditions, including cancer. These cells are characterized by their immature phenotype and suppressive effect on various immune effectors. In both human and mouse, there are two main subsets of MDSCs: polymorphonuclear (PMN)-MDSCs and mononuclear (Mo)-MDSCs. Thus, strategies to regulate MDSC-mediated immunosuppression could result in the enhancement of anticancer immune responses. Oxaliplatin, a platinum-based anticancer agent, is widely used in clinical settings. It is known to induce cell death by interfering with double-stranded DNA and interrupting its replication and transcription. In this study, we found that oxaliplatin has the potential to regulate MDSC-mediated immunosuppression in cancer. First, oxaliplatin selectively depleted MDSCs, especially Mo-MDSCs, but only minimally affected T cells. In addition, sublethal doses of oxaliplatin eliminated the immunosuppressive capacity of MDSCs and induced the differentiation of MDSCs into mature cells. Oxaliplatin treatment diminished the expression of the immunosuppressive functional mediators arginase 1 (ARG1) and NADPH oxidase 2 (NOX2) in MDSCs, while an MDSC-depleting agent, gemcitabine, did not downregulate these factors significantly. Oxaliplatin-conditioned MDSCs had no tumor-promoting activity in vivo. In addition, oxaliplatin modulated the intracellular NF-κB signaling in MDSCs. Thus, oxaliplatin has the potential to be used as an immunoregulatory agent as well as a cytotoxic drug in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.